Runners and would-be runners have been urged to ensure they have considered the best options for their eyesight if they are inspired to be more active by this year’s London Marathon.
The final of the 2023 SCOPE IP Bursary Awards took place on Thursday 29 June 2023. The award, now in its second year, attracted many entries the quality of which were extremely high.
Following the outbreak of the war in Ukraine in February last year, the charity Ophthalmic Aid to Eastern Europe (OAEE) set about trying to gather ophthalmic equipment and supplies for Ukraine.
In what she called “a giant leap for orthoptists”, Liz Shilling (known professionally as Liz Tomlin), was installed this week as Master of The Worshipful Company of Spectacle Makers, the first orthoptist ever to serve as Master in the Company’s almost 400 year-old history.
5 February 2020
| Salina Zaheen, Yasmin Riaz
|
Ophthalmology
With 90% of the world’s visually impaired living in developing countries, Pakistan is no exception to this on-going global healthcare challenge. Despite massive leaps over the last few decades in targeting this issue, the World Health Organisation (WHO) reports that...
In this retrospective review of 217 patients with Whipple’s disease (WD), the authors reviewed the presentations of those with ocular manifestations. Ocular signs of WD are under recognised, frequently resulting in misdiagnosis and mismanagement. Mayo Data Explorer, a Mayo Clinic...
3 October 2022
| Rosie Brennan, Bernadetha Robert Shilio, Marcia Zondervan, Covadonga Bascaran
|
Ophthalmology
Global Citizen post - a new challenge I was looking for a new challenge. I had been in the same consultant post with a subspecialty interest in paediatrics and strabismus for 17 years and was rattling around in an empty...
A team led by Siegfried Wagner and Pearse Keane of Moorfields Eye Hospital and UCL Institute of Ophthalmology (and spanning UCL institutions) has identified markers that indicate the presence of Parkinson’s disease in patients on average seven years before clinical presentation.
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...